Jeffrey Simmons Net Worth

The estimated Net Worth of Jeffrey N Simmons is at least $21.4 million dollars as of 12 August 2024. Mr. Simmons owns over 100,000 units of Elanco Animal Health Inc stock worth over $2,099,600 and over the last 15 years he sold ELAN stock worth over $3,494,165. In addition, he makes $15,801,800 as President, Chief Executive Officer et Director at Elanco Animal Health Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Simmons ELAN stock SEC Form 4 insiders trading

Jeffrey has made over 22 trades of the Elanco Animal Health Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of ELAN stock worth $1,301,000 on 12 August 2024.

The largest trade he's ever made was buying 100,000 units of Elanco Animal Health Inc stock on 12 August 2024 worth over $1,301,000. On average, Jeffrey trades about 6,297 units every 65 days since 2010. As of 12 August 2024 he still owns at least 145,000 units of Elanco Animal Health Inc stock.

You can see the complete history of Mr. Simmons stock trades at the bottom of the page.

Jeffrey Simmons biography

Jeffrey N. Simmons is the President, Chief Executive Officer and Director of the Company. Mr. Simmons as served as Elanco’s President and Chief Executive Officer and as a member of the Board since July 2018. Mr. Simmons served as the President of the Elanco Animal Health division of Lilly and Senior Vice President of Lilly from 2008 until September 2018. Prior to 2008, Mr. Simmons held various leadership roles for Elanco, including District Sales Manager, International Marketing Manager, Country Director for Brazil, Area Director for Western Europe and Executive Director for U.S. and Global Research & Development. Mr. Simmons’ experience described above, including his knowledge of Elanco and the animal health industry and his business and management experience, provides him with the qualifications and skills to serve as a director on Elanco’s Board.

What is the salary of Jeffrey Simmons?

As the President, Chief Executive Officer et Director of Elanco Animal Health Inc, the total compensation of Jeffrey Simmons at Elanco Animal Health Inc is $15,801,800. There are no executives at Elanco Animal Health Inc getting paid more.

How old is Jeffrey Simmons?

Jeffrey Simmons is 52, he's been the President, Chief Executive Officer et Director of Elanco Animal Health Inc since 2018. There are 15 older and 11 younger executives at Elanco Animal Health Inc. The oldest executive at Elanco Animal Health Inc is R. David Hoover, 74, who is the Independent Chairman of the Board.

What's Jeffrey Simmons's mailing address?

Jeffrey's mailing address filed with the SEC is C/O ELANCO ANIMAL HEALTH INCORPORATED, 2500 INNOVATION WAY, GREENFIELD, IN, 46140.

Insiders trading at Elanco Animal Health Inc

Over the last 6 years, insiders at Elanco Animal Health Inc have traded over $1,626,280,000 worth of Elanco Animal Health Inc stock and bought 657,104 units worth $14,225,149 . The most active insiders traders include Aktiengesellschaft Bayer Wo..., Scott D.Sachem Head Capital... et R David Hoover. On average, Elanco Animal Health Inc executives and independent directors trade stock every 38 days with the average trade being worth of $14,011,833. The most recent stock trade was executed by Michael J Harrington on 22 August 2024, trading 3,500 units of ELAN stock currently worth $51,975.

What does Elanco Animal Health Inc do?

elanco is a global animal health company. our vision: food and companionship enriching life. elanco fulfills this vision through three primary pursuits: - helping deliver a safe, more affordable, more abundant food supply by improving the health and performance of animals - helping pets live longer, healthier, higher-quality lives - improving food safety elanco employees are empowered to preserve elanco’s common culture of humility, discipline and involvement. we have a responsibility to connect and contribute to our cause, to be passionate about delivering solutions and value to our customers, and to embrace opportunities for personal and professional growth and development. through innovative products, quality systems and a shared vision, elanco strives daily to enhance animal health—and enrich the lives of people worldwide.

Complete history of Mr. Simmons stock trades at Lilly(Eli) & Co et Elanco Animal Health Inc

Elanco Animal Health Inc executives and stock owners

Elanco Animal Health Inc executives and other stock owners filed with the SEC include:

• Jeffrey Simmons,
  President, Chief Executive Officer, Director
• Sarena Lin,
  Executive Vice President, Global Marketing, Corporate Strategy and Transformation
• David Kinard,
  Executive Vice President of Human Resources
• David Urbanek,
  Executive Vice President - Manufacturing, Quality
• Aaron Schacht,
  Executive Vice President - Innovation, Regulatory, Business Development
• Todd Young,
  Chief Financial Officer, Executive Vice President
• Jeffrey N. Simmons,
  Pres, CEO & Director
• Todd S. Young,
  Exec. VP of Corp. Governance and Strategy & CFO
• R. David Hoover,
  Independent Chairman of the Board
• Kapila Anand,
  Independent Director
• Lawrence Kurzius,
  Independent Director
• Michael Harrington,
  Independent Director
• John Bilbrey,
  Independent Director
• Denise Scots-Knight,
  Independent Director
• Kirk McDonald,
  Independent Director
• Deborah Kochevar,
  Independent Director
• Art Garcia,
  Independent Director
• Joshua Smiley,
  Independent Director
• Aarti Shah,
  Independent Director
• David Ricks,
  Independent Director
• Carl McMillian,
  Independent Director
• James Meer,
  Chief Accounting Officer, Vice President
• Ramiro Cabral,
  Executive Vice President - Elanco International
• Michael-Bryant Hicks,
  Executive Vice President, General Counsel, Corporate Secretary
• Larbi Van Lier,
  Sr. VP of Asia
• Shawn McKee,
  Sr. VP of U.S. Companion Animal
• David Alan Urbanek,
  Exec. VP of Manufacturing & Quality
• Ramiro Martin Cabral,
  Exec. VP of Elanco International
• Racquel Harris Mason,
  Exec. VP & Chief Marketing Officer
• Marcela A. Kirberger,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Tiffany Ann Kanaga,
  Head of Investor Relations
• David S. Kinard,
  Exec. VP of HR Corp. Affairs & Admin.
• Chris Keeley,
  Sr. VP & Chief Information Officer
• James M. Meer,
  VP & Chief Accounting Officer
• De Simas Jose Manuel Correia,
  SEE REMARKS
• Lilly & Co Eli,
  10% owner
• Timothy J Bettington,
  SEE REMARKS
• Aktiengesellschaft Bayer Wo...,
  
• Racquel Harris Mason,
  See Remarks
• Dirk Ehle,
  Ex VP & Pres Elanco Europe
• Joyce J. Lee,
  Ex VP Prs US Pet Hlth Com Op
• Rajeev A. Modi,
  SEE REMARKS
• Paul Herendeen,
  
• Marcela A. Kirberger,
  SEE REMARKS
• William F Doyle,
  
• Scott D.Sachem Head Capital...,
  
• Brabander Ellen De,
  SEE REMARKS
• Shiv O'neill,
  GC AND CORP SEC
• Grace Mc Ardle,
  EVP, MANUFACTURING AND QUALITY